Orthocell (ASX:OCC) has launched its peripheral nerve repair product “Remplir” for the first time in Singapore. This marks an early milestone ahead of the previously planned launch in the first quarter of 2025.

Remplir is made from a collagen-based material that provides a protective environment for the nerves during the healing process. It acts as a wrap or conduit for the nerve, protecting it from external stress and promoting regeneration by creating a stable, pressure-free environment.

Orthocell has secured its first order through its distribution partner Device Technologies Asia (DVT Asia). The sale comes just two months after the Singapore Health Sciences Authority approved the device in October 2024.

DVT Asia has already established relationships with target customers including plastic surgeons and orthopedic surgeons from major surgical centers.

Orthocel expects further sales growth and increased surgeon recruitment in the new year.

The stock is trading 6% higher at $1.06.